Charter Needs to Be Second-Time Lucky

Related Link: 

Charter and Time Warner Cable both need to do a deal to maintain their lofty valuations. But Time Warner Cable may have the upper hand.

Biogen's Tough Treatment from Wall Street

Related Link: 

High expectations for Biogen’s multiple-sclerosis drug are a significant obstacle for the stock.

PepsiCo to Replace Aspartame in Diet Pepsi in U.S.

Related Link: 

PepsiCo Inc. it will remove aspartame from Diet Pepsi in the U.S. and replace it with sucralose, another artificial sweetener, in a bid to reverse plunging sales.

How to Tame the Apple Watch

Related Link: 

Life doesn’t have to be reduced to a series of unnecessary disruptions on your wrist.

Abercrombie Dials Back Sex

Related Link: 

The retailer is dialing back its sex-tinged marketing and putting an end to hiring sales staff on attractiveness.

MetLife Could Take Page From GE, Analysts Say

Related Link: 

Credit Suisse analysts said General Electric’s decision to exit from banking could be a precursor to a similar move to slim down by MetLife.

Testing Out Robo Advisers

Related Link: 

We looked at automated investment services from startups and financial giants. Advice on how to choose.

Crystal Ball: Send Us Your Guess for the Nasdaq Composite

Related Link: 

Our weekly prediction feature looks at the Nasdaq index, which set records on both Thursday and Friday.

HSBC Would Need Divorce Not Move to Shed U.K. Issues

Related Link: 

HSBC is again considering moving its headquarters outside the U.K. because of the costs imposed by regulation. It can’t get away that easily.

Problems Found With Glaxo's Malaria Vaccine

Related Link: 

GlaxoSmithKline’s malaria vaccine, the world’s most advanced, loses effectiveness over time, even with a booster shot, according to new clinical-trial results.

Syndicate content